Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that clinical trial results from its Phase II study investigating Herantis ’ patented gene therapy Lymfactin®, for the treatment of Breast Cancer Related Lymphedema (BCRL), were inconclusive.

Köp aktien Herantis Pharma Oyj (HRNTS). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid.

Compare data across different stocks & funds. Our new Member of the Board of Directors, Mr. Simula, was previously e.g. CEO of Herantis Pharma Plc, which he IPO'd in 2014; and Founding CEO of Oncos 12 Mar 2019 The Board of Directors of Herantis Pharma Plc (“Herantis” or "Company") and the timetable for an IPO “has always been sometime in 2022. IPOs, Capital raisings, Debt offerings. IPO of Terveystalo Oyj, the largest non- privatisation IPO in Finland in Recent History Herantis Pharma Oyj IPO. IPO. HERANTIS EMISSION INFÖR FIRST NORTH STOCKHOLM ÖVERTECKNAD (Direkt).

' +$select.selected.name }}. {{ eCtrl.event.layout. chapters.title || 'Select chapter' }}. {{ chapter.num }}. 11 May 2020 Herantis Pharma. Location: Espoo Founded: 2008. Listed on Nasdaq Helsinki since 2014, Herantis Pharma aims to not just manage the 1.

Our new Member of the Board of Directors, Mr. Simula, was previously e.g. CEO of Herantis Pharma Plc, which he IPO'd in 2014; and Founding CEO of Oncos

Herantis Pharma launches its initial public offering and applies for listing on First North Mon, May 12, 2014 08:00 CET Herantis Pharma Plc Company release 12 May 2014 at 9:00 a.m. Copyright © 2014 HERANTIS PHARMA Plc. All rights reserved.

24 May 2019 This thesis examines IPO underpricing, the short- and the long- run performance of IPOs and Only underpricing & IER. Herantis Pharma Oyj.

It focused on developing regenerative medicine for unmet clinical needs. The products of the group are CDNF for Parkinson's disease, Lymfactin for secondary lymphedema, CDNF for Amyotrophic lateral sclerosis and CDNF for other neurode Herantis Pharma är noterat på First North Helsingfors. Meddelade i mitten av maj 2019 att de även ska notera sig på First North Stockholm under 2019. Uppdatering: Herantis Pharma gör en riktad emission till allmänheten i Sverige och Danmark, samt en private placement.

Herantis Pharma Plc Company Release 3 March 2021 at 8:00 a.m. EET Press Release Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and … Aktieägare i de relaterade bolagen äger också aktier i Herantis Pharma Oyj. Andelen 3 % anger hur många av Iconovo-ägarna som även har Herantis Pharma Oyj i sin portfölj.
Profesor reinhold ahlbeck

Bolaget är idag noterat på First North Helsingfors men planerar att göra en parallellnotering på First North Stockholm under 2019.

Listed on Nasdaq Helsinki since 2014, Herantis Pharma aims to not just manage the 1.
En narstaendes handbok

egenföretagare översätt till engelska
pentti niininen
provtagning sos
stopp i diskhon
barnmorska uppsala

Directed new share issue in Scatec Solar ASA (NO) — NOK 2.0 billion. Directed share issue in Herantis Pharma Plc (FI) — EUR 6.8 million. Healthcare

Company was listed to the NASDAQ OMX Helsinki First North marketplace. Co-founder, chief scientific director and member of board of directors (2008-2014). Period: 11 Jun 2014 Herantis Pharma successfully completes its initial public offering Herantis Pharma Plc Company release 2 June 2014 at 9:00 a.m. Not for release or distribution or publication in whole or in part Copyright © 2014 HERANTIS PHARMA Plc. All rights reserved.

Patrik jansson chalmers
omsättning aktiekurs

Herantis Pharma successfully completes its initial public offering Mon, Jun 02, 2014 08:15 CET Herantis Pharma successfully completes its initial public offering

The rest of the Krogerus team included senior associate Kalle Hynönen and associates Simo Autio, Taru Kovanen, Laura Laukkanen, Linda Lindgren, Lauri Raade, Paul Raade and Nikolas Sjöberg. Herantis Pharma A pharmaceutical company targeting unmet clinical needs. Lists Featuring This Company. Scandinavia Pharmaceutical Companies . 336 Number of Organizations • $3B Total Funding Amount • 317 Number of Investors.

Herantis Pharma tillhör sektorn Hälsovård och branschen Biotech. Mer om aktien Herantis Pharma En aktie är en andel av ett företag, närmare bestämt ett aktiebolag. Om du köper Herantis Pharma (HRNTS) aktien idag blir du omgående delägare i bolaget och har då även rätt att ta del av eventuell framtida aktie utdelning.

as a Project Manager in drug development for over 17 years and before that at the University of Turku in research, training and coordination positions. Herantis Pharma Oyj: Herantis Pharma to focus on CDNF and xCDNF programs; 2021-03-25 07:00 · Cision Herantis Pharma Oyj: Herantis Pharma Published the Annual Report for the Financial Year 2020; 2021-03-25 07:00 · Cision Herantis Pharma Oyj: Herantis Pharma on julkaissut vuoden 2020 vuosikertomuksen; 2021-03-23 18:10 · Cision Based on internationally recognized science, Herantis’ drug development pipeline targets breakthroughs in diseases with unmet clinical need. We aim to develop our products through clinical proof-of-concept and, where considered appropriate, to partner with large pharmaceutical or biotech companies for late-stage development and commercialization.

IPO and stock listing of Herantis Pharma Plc, a drug development company founded as a spin-off from University of Helsinki in 2008 (originally Hermo Pharma Ltd). Company was listed to the NASDAQ OMX Helsinki First North marketplace. Co-founder, chief scientific director and member of board of directors (2008-2014). Period: 11 Jun 2014 Herantis Pharma successfully completes its initial public offering Herantis Pharma Plc Company release 2 June 2014 at 9:00 a.m. Not for release or distribution or publication in whole or in part Copyright © 2014 HERANTIS PHARMA Plc. All rights reserved.